Stockholders Equity (Tables)
|
6 Months Ended |
Jun. 30, 2024 |
|---|
| Stockholders Equity [Abstract] |
|
| Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders |
As of June 30, 2024, the Company
had the following outstanding warrants to purchase Common Stock issued to stockholders: | Warrant |
| Issuance Date |
| Expiration
Date |
| Exercise
Price
Per Share |
|
| Number of
Shares of
Common Stock
Underlying
Warrants |
|
| Public Warrants |
| IPO (December 13, 2018) |
| October 28, 2024 |
| |
11.50 |
|
| |
3,500,000 |
|
| 2021 Registered Direct Offering Warrants |
| SPA (July 28, 2021) |
| January 28, 2027 |
| |
5.00 |
|
| |
2,812,501 |
|
| Merger Warrants |
| March 15, 2024 |
| January 28, 2027 |
| |
5.00 |
|
| |
2,166,497 |
|
| Private Placement Warrants |
| March 15, 2024 |
| July 9, 2026 |
| |
0.2311 |
|
| |
108,208,500 |
|
| Agents Warrants |
| March 15, 2024 |
| July 9, 2026 |
| |
0.2311 |
|
| |
9,523,809 |
|
| |
| |
| |
| |
|
|
| |
126,211,307 |
|
|
| Schedule of Fair Value Of The Agents Warrants Using The Black-Scholes Model |
The Company determined the fair value
of the Agents Warrants using the Black-Scholes model as of March 5, 2024. The main assumptions used are as follows: | Underlying value of Common Stock ($) |
| |
0.23 |
|
| Exercise price ($) |
| |
0.23 |
|
| Expected volatility (%) |
| |
100.6 |
|
| Expected terms (years) |
| |
2.32 |
|
| Risk-free interest rate (%) |
| |
4.4 |
|
|
| Schedule of Options Granted to Purchase |
A summary of options granted to purchase the Company’s Common Stock under the Company’s share option plans is as follows: | |
| For the Six Months Ended
June 30, 2024 |
|
| |
| Number of
Options |
|
| Weighted
Average
Exercise Price |
|
| Aggregate
Intrinsic
Value |
|
| Outstanding at the beginning of period |
| |
5,280,711 |
|
| $ |
0.54 |
|
| $ |
72 |
|
| Granted |
| |
- |
|
| $ |
- |
|
| |
|
|
| Forfeited |
| |
(206,231 |
) |
| $ |
0.40 |
|
| |
|
|
| Expired |
| |
(3,066 |
) |
| $ |
0.41 |
|
| |
|
|
| Exercised |
| |
- |
|
| $ |
- |
|
| |
|
|
| Outstanding at the end of period |
| |
5,071,414 |
|
| |
0.55 |
|
| $ |
214 |
|
| Exercisable at the end of period |
| |
3,410,134 |
|
| |
0.57 |
|
| |
|
|
| Weighted average remaining contractual life of outstanding options – years as of June 30, 2024 |
| |
6.04 |
|
| |
|
|
| |
|
|
|
| Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock |
As of June 30, 2024, the Company
had the following outstanding compensation related warrants to purchase Common Stock: | Warrant |
| Issuance
Date |
| Expiration
Date |
|
| Exercise
Price
Per Share |
|
| Number of
Shares of
Common Stock
Underlying
Warrants |
|
| Private Warrants issued to scientific founders |
| November 27,
2017 |
| |
- |
|
| |
- |
|
| |
2,974 |
|
| Landlord Warrants* |
| March 15,
2024 |
| |
January 28,
2027 |
|
| |
5.00 |
|
| |
250,000 |
|
| |
| |
| |
|
|
| |
|
|
| |
252,974 |
|
|
| Schedule of Stock-Based Payment Expenses |
The following table sets forth the total stock-based payment expenses resulting from options granted, included in the statements of operations:
| |
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
| |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
| Research and development expenses, net |
|
|
(2 |
) |
|
|
84 |
|
|
|
63 |
|
|
|
171 |
|
| General and administrative |
|
|
79 |
|
|
|
187 |
|
|
|
191 |
|
|
|
275 |
|
| |
|
|
77 |
|
|
|
271 |
|
|
|
254 |
|
|
|
446 |
|
|